<code id='EA22BC26C2'></code><style id='EA22BC26C2'></style>
    • <acronym id='EA22BC26C2'></acronym>
      <center id='EA22BC26C2'><center id='EA22BC26C2'><tfoot id='EA22BC26C2'></tfoot></center><abbr id='EA22BC26C2'><dir id='EA22BC26C2'><tfoot id='EA22BC26C2'></tfoot><noframes id='EA22BC26C2'>

    • <optgroup id='EA22BC26C2'><strike id='EA22BC26C2'><sup id='EA22BC26C2'></sup></strike><code id='EA22BC26C2'></code></optgroup>
        1. <b id='EA22BC26C2'><label id='EA22BC26C2'><select id='EA22BC26C2'><dt id='EA22BC26C2'><span id='EA22BC26C2'></span></dt></select></label></b><u id='EA22BC26C2'></u>
          <i id='EA22BC26C2'><strike id='EA22BC26C2'><tt id='EA22BC26C2'><pre id='EA22BC26C2'></pre></tt></strike></i>

          knowledge

          knowledge

          author:entertainment    Page View:423
          Two business miniatures talk to each other on coin stacks that are sandwiched by a syringe and a stethoscope — coverage from STAT
          Adobe

          For all the flak they get, the country’s four biggest pharmacy benefit managers reported a surprisingly tame average profit margin in the first three quarters of 2023: 4.5%, less than a third of their drugmaker peers.

          But don’t take their numbers as gospel, experts warned.

          advertisement

          “It’s really easy to move money around inside the books of a vertically integrated organization,” said Karen Van Nuys, a senior fellow at the USC Schaeffer Center for Health Policy and Economics. “If one segment of your vertically integrated organization is not publishing any financial data, it’s a good place to hide stuff.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Walensky prepares to leave CDC — and Congress — behind
          Walensky prepares to leave CDC — and Congress — behind

          OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

          read more
          FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial
          FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

          MarkJ.Terrill/APAfollow-upstudyofafirst-of-its-kindcancertreatmentmayreflectsystemicbiases,theFoodan

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          The Karikó problem: Lessons for funding basic research

          AdobeNewscientificinstitutesarespringingupallovertheplacethesedays:ArcadiaScience,NewScience,ArcInst